Case Report: First report of peritoneal dialysis-related peritonitis caused by Pseudomonas fulva
-
By
-
Tian Feng
-
Yu Zhan
-
Yingmiao Zhang
-
Zhongxin Lu
-
May 25, 2026
-
Clinical Scorecard: First Description of Peritoneal Dialysis-Associated Peritonitis Due to Pseudomonas fulva
At a Glance
| Category | Detail |
|---|
| Condition | Peritoneal dialysis-associated peritonitis |
| Key Mechanisms | Infection caused by Pseudomonas fulva, an environmental opportunistic pathogen |
| Target Population | Patients undergoing peritoneal dialysis, particularly those with end-stage renal disease |
| Care Setting | Hospital, specifically intensive care unit (ICU) |
Key Highlights
- First reported case of peritoneal dialysis-related peritonitis due to Pseudomonas fulva
- Accurate identification of P. fulva using MALDI-TOF MS and 16S rRNA sequencing
- Patient treated successfully with intravenous cefotaxime
- Antimicrobial susceptibility testing showed sensitivity to all tested antibiotics
- Primary risk factors include end-stage renal disease and environmental contamination
Guideline-Based Recommendations
Diagnosis
- Utilize MALDI-TOF MS and 16S rRNA sequencing for accurate identification of P. fulva
Management
- Administer appropriate antibiotics based on susceptibility testing
Monitoring & Follow-up
- Monitor patient’s vital signs and complete blood count during treatment
Risks
- Risk factors include severe renal insufficiency, hypokalemia, and contamination during dialysis
Patient & Prescribing Data
Elderly patients with end-stage renal disease undergoing peritoneal dialysis
Cefotaxime was effective in treating the infection, with normalization of vital signs and laboratory parameters
Clinical Best Practices
- Implement standardized aseptic techniques for specimen collection
- Conduct timely processing of ascitic fluid specimens to prevent bacterial overgrowth
- Ensure thorough antimicrobial susceptibility testing before treatment
Related Resources & Content
